Improving our understanding of viruses to help develop new medicines

Based on research at University College London, Arrow Therapeutics has developed an array of potential candidates for novel anti-viral drugs. Basic Research by Professor Ian Charles into molecular pathogenicity led to the creation of a novel technology termed Transposon-mediated Differential Hybridisation (TMDH), which allows researchers to analyse the genes of a target organism.

Arrow therapeutics was purchased by Astra Zeneca in 2007 for around $150m in cash, generating large financial returns for the researchers and the university. The products being developed by the company work to combat important pathogens such as Hepatitis C and Respiratory Syncytial Virus (RSV): they could therefore have enormous impacts on healthcare, and potentially save many lives.

Policy areas

Related case studies

Media Enquiries
Policy Enquiries

Follow us on Twitter

View broadcast appearances on

Russell Group YouTube Channel